Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

First Report of Prostate-specific Membrane Antigen-targeted Immunotherapy in Prostate Cancer: The Future is Bright.

Lamb AD, Bryant RJ, Mills IG, Hamdy FC.

Eur Urol. 2018 Feb 16. pii: S0302-2838(18)30114-3. doi: 10.1016/j.eururo.2018.02.007. [Epub ahead of print] No abstract available.

PMID:
29458983
2.

Identification of potential therapeutic targets in prostate cancer through a cross-species approach.

Jurmeister S, Ramos-Montoya A, Sandi C, Pértega-Gomes N, Wadhwa K, Lamb AD, Dunning MJ, Attig J, Carroll JS, Fryer LG, Felisbino SL, Neal DE.

EMBO Mol Med. 2018 Feb 5. pii: e8274. doi: 10.15252/emmm.201708274. [Epub ahead of print]

3.

Diagnostic Pathways for Screen-detected Prostate Cancer: The Plot Thickens.

Hamdy FC, Lamb AD, Bryant RJ.

Eur Urol. 2017 Nov 28. pii: S0302-2838(17)30994-6. doi: 10.1016/j.eururo.2017.11.011. [Epub ahead of print] No abstract available.

PMID:
29195776
4.

Orient Expression: Solving the Mystery of Asian Prostate Cancer?

Lamb AD, Bryant RJ, Camilleri P, Hamdy FC.

Eur Urol. 2017 Nov 10. pii: S0302-2838(17)30969-7. doi: 10.1016/j.eururo.2017.10.030. [Epub ahead of print] No abstract available.

PMID:
29132711
5.

Systematic Review of Studies Reporting Positive Surgical Margins After Bladder Neck Sparing Radical Prostatectomy.

Bellangino M, Verrill C, Leslie T, Bell RW, Hamdy FC, Lamb AD.

Curr Urol Rep. 2017 Nov 7;18(12):99. doi: 10.1007/s11934-017-0745-0. Review.

6.

Reducing Mortality in the Ageing Patient: Treatment of the Primary Tumour Is Not Necessary.

Lamb AD, Brewster SF, Hamdy FC.

Eur Urol Focus. 2017 Oct;3(4-5):328-329. doi: 10.1016/j.euf.2017.10.008. Epub 2017 Oct 31.

PMID:
29097093
7.

Cradles and museums of Antarctic teleost biodiversity.

Dornburg A, Federman S, Lamb AD, Jones CD, Near TJ.

Nat Ecol Evol. 2017 Sep;1(9):1379-1384. doi: 10.1038/s41559-017-0239-y. Epub 2017 Jul 24.

PMID:
29046532
8.

Corrigendum to "Aiming for a holistic integrated service for men diagnosed with prostate cancer - Definitions of standards and skill sets for nurses and allied healthcare professionals" [Eur. J. Oncol. Nurs. 29 (2017) 31-38].

Lamb AD, Thompson S, Kinsella N, Gerbitz I, Chapman E, Putt L, Bennett S, Thankappannair V, Geoghegan L, Wright N, Stirton-Croft A, Nixon P, Styling A, Whitney D, Hodgson L, Punt L, Longmore J, Carter M, Petch B, Rimmer Y, Russell S, Hughes-Davies L, Mazhar D, Shah NC, Gnanapragasam VJ, Doble A, Bratt O, Kastner C.

Eur J Oncol Nurs. 2017 Oct;30:59. doi: 10.1016/j.ejon.2017.07.008. Epub 2017 Aug 31. No abstract available.

PMID:
29031314
9.

Changing face of robot-assisted radical prostatectomy in Melbourne over 12 years.

Sathianathen NJ, Lamb AD, Lawrentschuk NL, Goad JR, Peters J, Costello AJ, Murphy DG, Moon DA.

ANZ J Surg. 2017 Sep 18. doi: 10.1111/ans.14169. [Epub ahead of print]

PMID:
28922689
10.

The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory.

Sathianathen NJ, Geurts N, Nair R, Lawrentschuk N, Murphy DG, Lamb AD.

Future Oncol. 2017 Aug;13(20):1801-1807. doi: 10.2217/fon-2017-0074. Epub 2017 Aug 1.

11.

DESNT: A Poor Prognosis Category of Human Prostate Cancer.

Luca BA, Brewer DS, Edwards DR, Edwards S, Whitaker HC, Merson S, Dennis N, Cooper RA, Hazell S, Warren AY; CancerMap Group, Eeles R, Lynch AG, Ross-Adams H, Lamb AD, Neal DE, Sethia K, Mills RD, Ball RY, Curley H, Clark J, Moulton V, Cooper CS.

Eur Urol Focus. 2017 Mar 6. pii: S2405-4569(17)30025-1. doi: 10.1016/j.euf.2017.01.016. [Epub ahead of print]

12.

Aiming for a holistic integrated service for men diagnosed with prostate cancer - Definitions of standards and skill sets for nurses and allied healthcare professionals.

Lamb AD, Thompson S, Kinsella N, Gerbitz I, Chapman E, Putt L, Bennett S, Thankappannair V, Geoghegan L, Wright N, Stirton-Croft A, Nixon P, Styling A, Whitney D, Hodgson L, Punt L, Longmore J, Carter M, Petch B, Rimmer Y, Russell S, Hughes-Davies L, Mazhar D, Shah NC, Gnanapragasam VJ, Doble A, Bratt O, Kastner C.

Eur J Oncol Nurs. 2017 Aug;29:31-38. doi: 10.1016/j.ejon.2017.04.004. Epub 2017 May 11. Erratum in: Eur J Oncol Nurs. 2017 Oct;30:59.

PMID:
28720263
13.

Prostate-specific membrane antigen radioguided surgery: a promising utility.

Geurts N, Lamb AD, Lawrentschuk N, Murphy DG.

BJU Int. 2017 Jul;120(1):5-6. doi: 10.1111/bju.13838. No abstract available.

14.

Corrigendum to "Integration of Copy Number and Transcriptomics Provides Risk Stratification in Prostate Cancer: A Discovery and Validation Cohort Study" [EBioMedicine 2 (9) (2015) 1133-1144].

Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, Egevad LA, Russell R, Ramos-Montoya A, Vowler SL, Sharma NL, Kay J, Whitaker H, Clark J, Hurst R, Gnanapragasam VJ, Shah NC, Warren AY, Cooper CS, Lynch AG, Stark R, Mills IG, Grönberg H, Neal DE; CamCaP Study Group.

EBioMedicine. 2017 Mar;17:238. doi: 10.1016/j.ebiom.2017.03.010. Epub 2017 Mar 8. No abstract available.

15.

Mining Human Prostate Cancer Datasets: The "camcAPP" Shiny App.

Dunning MJ, Vowler SL, Lalonde E, Ross-Adams H, Boutros P, Mills IG, Lynch AG, Lamb AD.

EBioMedicine. 2017 Mar;17:5-6. doi: 10.1016/j.ebiom.2017.02.022. Epub 2017 Mar 2. No abstract available.

16.

Re: Diagnostic Accuracy of Multi-parametric MRI and TRUS Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study.

Kapoor J, Lamb AD, Murphy DG.

Eur Urol. 2017 Jul;72(1):151. doi: 10.1016/j.eururo.2017.02.014. Epub 2017 Feb 24. No abstract available.

PMID:
28238478
17.

Practical Polling for Prostate Cancer: AR-V7-based Treatment Selection.

Lamb AD, Lawrence MG, Sandhu S.

Eur Urol. 2017 Jun;71(6):883-885. doi: 10.1016/j.eururo.2016.12.028. Epub 2017 Jan 11. No abstract available.

PMID:
28089303
18.

Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.

Lalonde E, Alkallas R, Chua MLK, Fraser M, Haider S, Meng A, Zheng J, Yao CQ, Picard V, Orain M, Hovington H, Murgic J, Berlin A, Lacombe L, Bergeron A, Fradet Y, Têtu B, Lindberg J, Egevad L, Grönberg H, Ross-Adams H, Lamb AD, Halim S, Dunning MJ, Neal DE, Pintilie M, van der Kwast T, Bristow RG, Boutros PC.

Eur Urol. 2017 Jul;72(1):22-31. doi: 10.1016/j.eururo.2016.10.013. Epub 2016 Nov 1.

PMID:
27815082
19.

Evolution and oncological outcomes of a contemporary radical prostatectomy practice in a UK regional tertiary referral centre.

Gnanapragasam VJ, Thurtle D, Srinivasan A, Volanis D, George A, Lophatananon A, Stearn S, Warren AY, Lamb AD, Shaw G, Sharma N, Thomas BC, Tran MG, Neal DE, Shah NC.

BJU Int. 2016 Nov;118(5):779-784. doi: 10.1111/bju.13513. Epub 2016 May 24.

20.

HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer.

Ross-Adams H, Ball S, Lawrenson K, Halim S, Russell R, Wells C, Strand SH, Ørntoft TF, Larson M, Armasu S, Massie CE, Asim M, Mortensen MM, Borre M, Woodfine K, Warren AY, Lamb AD, Kay J, Whitaker H, Ramos-Montoya A, Murrell A, Sørensen KD, Fridley BL, Goode EL, Gayther SA, Masters J, Neal DE, Mills IG.

Oncotarget. 2016 Nov 15;7(46):74734-74746. doi: 10.18632/oncotarget.12543.

21.

Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.

Johnston TJ, Shaw GL, Lamb AD, Parashar D, Greenberg D, Xiong T, Edwards AL, Gnanapragasam V, Holding P, Herbert P, Davis M, Mizielinsk E, Lane JA, Oxley J, Robinson M, Mason M, Staffurth J, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Prescott S, Paul A, Powell P, Rosario D, Rowe E, Donovan JL, Hamdy FC, Neal DE; ProtecT study group.

Eur Urol. 2017 Mar;71(3):381-388. doi: 10.1016/j.eururo.2016.09.040. Epub 2016 Oct 6.

22.

Enantioselective Synthesis of 4- and 6-Azaindolines by a Cation-Directed Cyclization.

Lamb AD, Davey PD, Driver RW, Thompson AL, Smith MD.

Org Lett. 2016 Oct 6. [Epub ahead of print]

23.

Salvage robotic prostatectomy for radio recurrent prostate cancer: technical challenges and outcome analysis.

Zargar H, Lamb AD, Rocco B, Porpiglia F, Liatsikos E, Davis J, Coelho RF, Pow-Sang JM, Patel VR, Murphy DG.

Minerva Urol Nefrol. 2017 Feb;69(1):26-37. Epub 2016 Aug 31.

24.

Whole blood mRNA in prostate cancer reveals a four-gene androgen regulated panel.

Thomas BC, Kay JD, Menon S, Vowler SL, Dawson SN, Bucklow LJ, Luxton HJ, Johnston T, Massie CE, Pugh M, Warren AY, Barker P, Burling K, Lynch AG, George A, Burge J, Corcoran M, Stearn S, Lamb AD, Sharma NL, Shaw GL, Neal DE, Whitaker HC.

Endocr Relat Cancer. 2016 Oct;23(10):797-812. doi: 10.1530/ERC-16-0287. Epub 2016 Aug 30.

25.

Disrupting the Status Quo in Prostate Cancer Diagnosis.

Lamb AD, Zargar H, Murphy DG, Corcoran NM, Hovens CM.

Eur Urol. 2017 Feb;71(2):193-194. doi: 10.1016/j.eururo.2016.08.018. Epub 2016 Aug 21. No abstract available.

PMID:
27554242
26.

Gene regulatory mechanisms underpinning prostate cancer susceptibility.

Whitington T, Gao P, Song W, Ross-Adams H, Lamb AD, Yang Y, Svezia I, Klevebring D, Mills IG, Karlsson R, Halim S, Dunning MJ, Egevad L, Warren AY, Neal DE, Grönberg H, Lindberg J, Wei GH, Wiklund F.

Nat Genet. 2016 Apr;48(4):387-97. doi: 10.1038/ng.3523. Epub 2016 Mar 7.

PMID:
26950096
27.

The genetic classification of prostate cancer: what's on the horizon?

Ross-Adams H, Lamb AD.

Future Oncol. 2016 Mar;12(6):729-33. doi: 10.2217/fon.15.352. Epub 2016 Feb 9. No abstract available.

28.

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer.

Shaw GL, Whitaker H, Corcoran M, Dunning MJ, Luxton H, Kay J, Massie CE, Miller JL, Lamb AD, Ross-Adams H, Russell R, Nelson AW, Eldridge MD, Lynch AG, Ramos-Montoya A, Mills IG, Taylor AE, Arlt W, Shah N, Warren AY, Neal DE.

Eur Urol. 2016 Aug;70(2):214-8. doi: 10.1016/j.eururo.2015.10.042. Epub 2015 Nov 10.

29.

Towards "next-generation" prostate cancer screening.

Lamb AD, Bratt O.

Lancet Oncol. 2015 Dec;16(16):1579-80. doi: 10.1016/S1470-2045(15)00395-2. Epub 2015 Nov 10. No abstract available.

PMID:
26563501
30.

Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.

Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, Egevad LA, Russell R, Ramos-Montoya A, Vowler SL, Sharma NL, Kay J, Whitaker H, Clark J, Hurst R, Gnanapragasam VJ, Shah NC, Warren AY, Cooper CS, Lynch AG, Stark R, Mills IG, Grönberg H, Neal DE; CamCaP Study Group.

EBioMedicine. 2015 Jul 29;2(9):1133-44. doi: 10.1016/j.ebiom.2015.07.017. eCollection 2015 Sep.

31.

HES5 silencing is an early and recurrent change in prostate tumourigenesis.

Massie CE, Spiteri I, Ross-Adams H, Luxton H, Kay J, Whitaker HC, Dunning MJ, Lamb AD, Ramos-Montoya A, Brewer DS, Cooper CS, Eeles R; UK Prostate ICGC Group, Warren AY, Tavaré S, Neal DE, Lynch AG.

Endocr Relat Cancer. 2015 Apr;22(2):131-44. doi: 10.1530/ERC-14-0454. Epub 2015 Jan 5.

32.

Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.

Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, Zafarana G, Warren AY, Meng X, Thoms J, Grzadkowski MR, Berlin A, Have CL, Ramnarine VR, Yao CQ, Malloff CA, Lam LL, Xie H, Harding NJ, Mak DY, Chu KC, Chong LC, Sendorek DH, P'ng C, Collins CC, Squire JA, Jurisica I, Cooper C, Eeles R, Pintilie M, Dal Pra A, Davicioni E, Lam WL, Milosevic M, Neal DE, van der Kwast T, Boutros PC, Bristow RG.

Lancet Oncol. 2014 Dec;15(13):1521-32. doi: 10.1016/S1470-2045(14)71021-6. Epub 2014 Nov 13.

33.

The ETS family member GABPα modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer.

Sharma NL, Massie CE, Butter F, Mann M, Bon H, Ramos-Montoya A, Menon S, Stark R, Lamb AD, Scott HE, Warren AY, Neal DE, Mills IG.

Nucleic Acids Res. 2014 Jun;42(10):6256-69. doi: 10.1093/nar/gku281. Epub 2014 Apr 21.

34.

HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network.

Ramos-Montoya A, Lamb AD, Russell R, Carroll T, Jurmeister S, Galeano-Dalmau N, Massie CE, Boren J, Bon H, Theodorou V, Vias M, Shaw GL, Sharma NL, Ross-Adams H, Scott HE, Vowler SL, Howat WJ, Warren AY, Wooster RF, Mills IG, Neal DE.

EMBO Mol Med. 2014 May;6(5):651-61. doi: 10.1002/emmm.201303581.

35.

Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.

Robinson JL, Hickey TE, Warren AY, Vowler SL, Carroll T, Lamb AD, Papoutsoglou N, Neal DE, Tilley WD, Carroll JS.

Oncogene. 2014 Dec 11;33(50):5666-74. doi: 10.1038/onc.2013.508. Epub 2013 Dec 2.

36.

The transcriptional programme of the androgen receptor (AR) in prostate cancer.

Lamb AD, Massie CE, Neal DE.

BJU Int. 2014 Mar;113(3):358-66. doi: 10.1111/bju.12415. Review.

37.

Editorial Comment to White blood cell count is positively associated with benign prostatic hyperplasia.

Lamb AD.

Int J Urol. 2014 Mar;21(3):312. doi: 10.1111/iju.12270. Epub 2013 Aug 28. No abstract available.

38.

The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man.

Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY, Mills IG, Neal DE.

Cancer Cell. 2013 Jan 14;23(1):35-47. doi: 10.1016/j.ccr.2012.11.010. Epub 2012 Dec 20.

39.

CD4+ and CD8+ T-lymphocyte scores cannot reliably predict progression in patients with benign prostatic hyperplasia.

Lamb AD, Qadan M, Roberts S, Timlin H, Vowler SL, Campbell FM, Grigor K, Bartlett JM, McNeill SA.

BJU Int. 2011 Jul;108(2 Pt 2):E43-50. doi: 10.1111/j.1464-410X.2010.09787.x. Epub 2011 Apr 1.

40.

Meta-analysis showing the beneficial effect of α-blockers on ureteric stent discomfort.

Lamb AD, Vowler SL, Johnston R, Dunn N, Wiseman OJ.

BJU Int. 2011 Dec;108(11):1894-902. doi: 10.1111/j.1464-410X.2011.10170.x. Epub 2011 Mar 31. Review.

41.

Re: Derham C, Vohra RS, Homer-Vanniasinkam S. Academia and MMC: uncomfortable bed-fellows? Surgeon 2009; 7(7): 4-5.

Lamb AD.

Surgeon. 2009 Dec;7(6):382; author reply 382. No abstract available.

PMID:
20681385
42.

Plain radiography still is required in the planning of treatment for urolithiasis.

Lamb AD, Wines MD, Mousa S, Tolley DA.

J Endourol. 2008 Oct;22(10):2201-5. doi: 10.1089/end.2008.9716.

PMID:
18937584
43.

Detection of occult pneumothoraces in the significantly injured adult with blunt trauma.

Lamb AD, Qadan M, Gray AJ.

Eur J Emerg Med. 2007 Apr;14(2):65-7.

PMID:
17496677
44.

Pattern of recurrence changes in noninvasive bladder tumors observed during 2 decades.

Mariappan P, Smith G, Lamb AD, Grigor KM, Tolley DA.

J Urol. 2007 Mar;177(3):867-75; discussion 875.

PMID:
17296362
45.

Supplemental Content

Support Center